Scribe Therapeutics has filed for an initial public offering, seeking to list on the Nasdaq Global Market and raise funds to support its CRISPR-based medicines targeting cardiometabolic conditions, according to a July 6 announcement.
The California-based biotechnology company has not disclosed the amount it aims to raise through the IPO. According to Scribe’s prospectus filed July 2, most of the proceeds will be directed toward its lead asset STX-1150, an investigational epigenetic silencing therapy that recently entered human testing. The therapy is designed as a treatment for atherosclerotic cardiovascular disease by suppressing expression of the PCSK9 gene and lowering LDL cholesterol concentrations.
Scribe said it aims with STX-1150 to “improve on the real-world efficacy of small-molecule, antibody and siRNA therapies,” while delivering therapeutic benefits without permanently altering patients’ DNA sequence. The first-in-human study for STX-1150 began recently in Australia, with data expected in the first half of 2027.
In addition to STX-1150, Scribe is developing two other assets: STX-1200 for reducing elevated lipoprotein(a) levels and STX-1400 for treating severely high triglycerides. Both are still in preclinical development. Funds from the proposed IPO would also support advancement of these programs.
The company has not specified when it plans to close its IPO. While Scribe remains early in drug development, it has already secured agreements with major pharmaceutical companies Sanofi and Eli Lilly.
With this move, Scribe enters a public market environment that has been challenging in recent years for early-stage biotechs and those working on newer technologies. Ben Zercher, senior analyst at PitchBook, said last month, "where the pandemic-era class sold preclinical optionality, Parabilis and the 2026 cohort are being priced on de-risked clinical programs with clear regulatory paths." Recent record-setting biotech IPOs include Parabilis Medicines' $670 million raise in June and Kailera Therapeutics' $625 million offering earlier this year.
